Outcome of Board Meeting
Unaudited Financial Results for the quarter ended on June 30, 2017.11-08-2017
11-08-2017
Will recall of tablets impact Cadila?
Zydus Pharmaceuticals US Inc is recalling from the American market over 3.31 lakh bottles of Divalproex Sodium delayed release tablets used for the treatment of seizures and manic episodes in...10-08-2017
Father-son duo turn family drug firm Cadila into world beater
Cadila Healthcare, run by Pankaj and son Shravil Patel, earned the title of top generic drug manufacturer, despite regulatory scrutiny and withering competition in the US10-08-2017
Zydus Cadila gets USFDA nod for high blood pressure, heart disorder drug
The hypertension drug is used to treat chest pain, certain heart rhythm disorders09-08-2017
Press Release / Media Release
Zydus receives final approval from the USFDA for Diltiazem Hydrochloride Extended-Release Capsules USP.09-08-2017
Press Release / Media Release
Zydus receives tentative approval from the USFDA for Abacavir and Lamivudine Tablets USP08-08-2017
Zydus Cadila gets US FDA nod to market anti-dementia drug
Zydus Cadila today said it has received final nod from the US health regulator to market Memantine Hydrochloride extended-release capsules used for the treatment of dementia of Alzheimer's type....05-08-2017
Press Release
Zydus receives final approval from the USFDA for Memantine Hydrochloride Extended-Release Capsules05-08-2017
Zydus gets USFDA nod for brain tumour, hyper tension drugs
Cadila Healthcare Ltd (Zydus Cadila) has received final approval from the USFDA to market Temozolomide capsules in strengths of 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, and 250 mg. Temozolomide...01-08-2017
Press Release
Zydus receives final approval from the USFDA for Temozolomide Capsules and Nadolol Tablets USP.01-08-2017